Mark Marconi
Family Medicine · Wharton, TXNPI 1982656583
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 301 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,270 and has fallen 80.0% since, to $254 in 2023.
Across 301 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$900
- Sanofi-aventis U.S. LLC$581
- Novo Nordisk$497
- Boehringer Ingelheim$371
- AstraZeneca$353
- Merck$322
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,596100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $900 |
| Sanofi-aventis U.S. LLC | 34 | $581 |
| Novo Nordisk | 38 | $497 |
| Boehringer Ingelheim | 23 | $371 |
| AstraZeneca | 20 | $353 |
| Merck | 22 | $322 |
| Novartis | 13 | $204 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $184 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $161 |
| Pfizer | 8 | $157 |
| Abbott | 12 | $123 |
| Lilly USA, LLC | 8 | $123 |
| Amgen | 6 | $99 |
| GSK | 6 | $97 |
| Johnson & Johnson | 4 | $64 |
| Astellas Pharma US Inc | 4 | $53 |
| Indivior Inc. | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 3 | $36 |
| Boston Scientific | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Shield Therapeutics Inc | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $8 |
How this compares
$4,611 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 16 | $439 |
| Losartan Potassium | 15 | $192 |
| Latanoprost | 11 | $167 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Wharton
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.